MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

Search

Ipsen SA.

Suletud

SektorRahandus

103.8 0.1

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

103.5

Max

104

Põhinäitajad

By Trading Economics

Sissetulek

-118M

114M

Müük

71M

1.8B

P/E

Sektori keskmine

24.286

24.968

Dividenditootlus

1.38

Kasumimarginaal

6.249

Töötajad

5,358

EBITDA

228M

710M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+16.92% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

1.38%

4.18%

Järgmine tulemuste avaldamine

31. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

8.6B

Eelmine avamishind

103.7

Eelmine sulgemishind

103.8

Uudiste sentiment

By Acuity

36%

64%

136 / 538 Pingereas Finance

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Ipsen SA. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. dets 2024, 07:05 UTC

Market Talk

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Ipsen SA. Prognoos

Hinnasiht

By TipRanks

16.92% tõus

12 kuu keskmine prognoos

Keskmine 121.71 EUR  16.92%

Kõrge 148 EUR

Madal 100 EUR

Põhineb 7 Wall Streeti analüütiku instrumendi Ipsen SA. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

7 ratings

3

Osta

3

Hoia

1

Müü

Tehniline skoor

By Trading Central

99.85 / 104Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

136 / 538 Pingereas Rahandus

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.